Literature DB >> 14609838

Globe conserving treatment of the only eye in bilateral retinoblastoma.

V Lee1, J L Hungerford, C Bunce, F Ahmed, J E Kingston, P N Plowman.   

Abstract

AIMS: To quantify the rates of eye preservation and patient survival, local tumour relapse and recurrence, and development of new tumours in the remaining eye of children with bilateral retinoblastoma with one eye already enucleated. Also, in the same children, to describe the types of primary and secondary treatment procedures, and to define the anatomical outcome.
METHODS: This is a retrospective observational case series report. The study participants consisted of 107 patients with bilateral retinoblastoma with one eye enucleated within 1 month of baseline examination and had their remaining eye treated conservatively. The main outcome measure were: primary treatment failures, new tumours, enucleation of the only eye, death, remission, and anatomical outcomes (retinal detachment, vitreous haemorrhage, and cataract).
RESULTS: The median age at diagnosis was 8.4 (range 0.2-44, SD 10.1) months with a median ophthalmic follow up of 44.3 (8.1-114, SD 10.1) months. In 22 of the 107 patients (21%) the treated eye was in Reese Ellsworth groups I or II and in the remaining 85 (79%) in groups III-V at diagnosis. The primary treatment was cryotherapy in 14% (15/107) of eyes, radioactive plaque brachytherapy in 3.7% (4/107), and chemotherapy in 10% (11/107). It was lens sparing radiotherapy in 37% (40/107), whole eye radiotherapy in 29% (31/107), combined radiotherapy and chemotherapy in 2.8% (3/107), chemothermotherapy in 0.9% (1/107), and combined focal therapy in 1.8% (2/107). The primary treatment failed to achieve local tumour control during the follow up period in 37% (40/107) of eyes. In 17 eyes failure was due to inadequate control of the presenting tumour, in 16 to development of a new tumour, and in eight eyes to a combination of both. 35 (88%) of the 40 failures were managed by secondary conservative treatment and the remaining five were treated by enucleation of the only eye. There were eight (7.4%) deaths and the 3 year survival rate was 93% (100/108). Anatomical results included vitreous haemorrhage in four cases, tractional retinal detachment also in four cases, and 24 children required cataract surgery.
CONCLUSIONS: Aggressive conservative treatment achieved a good rate of globe salvage without impairing survival.

Entities:  

Mesh:

Year:  2003        PMID: 14609838      PMCID: PMC1771893          DOI: 10.1136/bjo.87.11.1374

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  19 in total

1.  Retinoblastoma.

Authors:  R M Ellsworth
Journal:  Mod Probl Ophthalmol       Date:  1977

2.  Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors.

Authors:  C L Shields; J A Shields; J Cater; I Othmane; A D Singh; B Micaily
Journal:  Ophthalmology       Date:  2001-11       Impact factor: 12.079

3.  Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation.

Authors:  Carol L Shields; Santosh G Honavar; Anna T Meadows; Jerry A Shields; Hakan Demirci; Arun Singh; Debra L Friedman; Thomas John Naduvilath
Journal:  Am J Ophthalmol       Date:  2002-05       Impact factor: 5.258

4.  Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma.

Authors:  Carol L Shields; Santosh G Honavar; Jerry A Shields; Hakan Demirci; Anna T Meadows; Thomas John Naduvilath
Journal:  Arch Ophthalmol       Date:  2002-04

5.  Ectopic intracranial retinoblastoma in childhood.

Authors:  J E Kingston; P N Plowman; J L Hungerford
Journal:  Br J Ophthalmol       Date:  1985-10       Impact factor: 4.638

6.  Mortality from second tumors among long-term survivors of retinoblastoma.

Authors:  C Eng; F P Li; D H Abramson; R M Ellsworth; F L Wong; M B Goldman; J Seddon; N Tarbell; J D Boice
Journal:  J Natl Cancer Inst       Date:  1993-07-21       Impact factor: 13.506

7.  Clinicopathologic features of retinoblastoma after primary chemoreduction.

Authors:  N E Bechrakis; N Bornfeld; A Schueler; S E Coupland; G Henze; M H Foerster
Journal:  Arch Ophthalmol       Date:  1998-07

8.  Bilateral retinoblastoma: the prognosis for vision.

Authors:  C Migdal
Journal:  Br J Ophthalmol       Date:  1983-09       Impact factor: 4.638

9.  Retinoblastoma in Great Britain 1969-80: incidence, treatment, and survival.

Authors:  B M Sanders; G J Draper; J E Kingston
Journal:  Br J Ophthalmol       Date:  1988-08       Impact factor: 4.638

10.  Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide.

Authors:  N J Winick; R W McKenna; J J Shuster; N R Schneider; M J Borowitz; W P Bowman; D Jacaruso; B A Kamen; G R Buchanan
Journal:  J Clin Oncol       Date:  1993-02       Impact factor: 44.544

View more
  10 in total

1.  High-resolution MRI using orbit surface coils for the evaluation of metastatic risk factors in 143 children with retinoblastoma: Part 1: MRI vs. histopathology.

Authors:  Selma Sirin; Marc Schlamann; Klaus A Metz; Norbert Bornfeld; Bernd Schweiger; Markus Holdt; Petra Temming; Michael M Schuendeln; Sophia L Goericke
Journal:  Neuroradiology       Date:  2015-06-04       Impact factor: 2.804

Review 2.  Management of retinoblastoma in children: current status.

Authors:  Guillermo Chantada; Paula Schaiquevich
Journal:  Paediatr Drugs       Date:  2015-06       Impact factor: 3.022

3.  Vitreous Disease in Retinoblastoma: Clinical Findings and Treatment.

Authors:  Jasmine H Francis; Larissa A Habib; David H Abramson
Journal:  Adv Ophthalmol Optom       Date:  2017-08

4.  High-resolution MRI using orbit surface coils for the evaluation of metastatic risk factors in 143 children with retinoblastoma: Part 2: new vs. old imaging concept.

Authors:  Selma Sirin; Marc Schlamann; Klaus A Metz; Norbert Bornfeld; Bernd Schweiger; Markus Holdt; Petra Temming; Michael M Schuendeln; Sophia L Goericke
Journal:  Neuroradiology       Date:  2015-05-08       Impact factor: 2.804

Review 5.  Retinoblastoma.

Authors:  Helen Dimaras; Timothy W Corson; David Cobrinik; Abby White; Junyang Zhao; Francis L Munier; David H Abramson; Carol L Shields; Guillermo L Chantada; Festus Njuguna; Brenda L Gallie
Journal:  Nat Rev Dis Primers       Date:  2015-08-27       Impact factor: 52.329

6.  Clinical results of chemotherapy based treatment in retinoblastoma patients: a single center experience.

Authors:  Hyery Kim; Ji Won Lee; Hyoung Jin Kang; Hyeon Jin Park; Yoon Yi Kim; Hee Young Shin; Young Suk Yu; Il Han Kim; Hyo Seop Ahn
Journal:  Cancer Res Treat       Date:  2008-12-31       Impact factor: 4.679

7.  Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma.

Authors:  David H Abramson; Anthony B Daniels; Brian P Marr; Jasmine H Francis; Scott E Brodie; Ira J Dunkel; Y Pierre Gobin
Journal:  PLoS One       Date:  2016-01-12       Impact factor: 3.240

8.  Pharmacokinetics, Tissue Localization, Toxicity, and Treatment Efficacy in the First Small Animal (Rabbit) Model of Intra-Arterial Chemotherapy for Retinoblastoma.

Authors:  Anthony B Daniels; Michael T Froehler; Janene M Pierce; Amy H Nunnally; M Wade Calcutt; Thomas M Bridges; David C LaNeve; Phillip E Williams; Kelli L Boyd; Michelle L Reyzer; Craig W Lindsley; Debra L Friedman; Ann Richmond
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-01-01       Impact factor: 4.799

9.  Current Treatment of Bilateral Retinoblastoma: The Impact of Intraarterial and Intravitreous Chemotherapy.

Authors:  Jasmine H Francis; Nelli Roosipu; Ariana M Levin; Scott E Brodie; Ira J Dunkel; Y Pierre Gobin; David H Abramson
Journal:  Neoplasia       Date:  2018-06-22       Impact factor: 5.715

10.  Constitutive RB1 mutation in a child conceived by in vitro fertilization: implications for genetic counseling.

Authors:  Raquel H Barbosa; Fernando R Vargas; Evandro Lucena; Cibele R Bonvicino; Héctor N Seuánez
Journal:  BMC Med Genet       Date:  2009-07-29       Impact factor: 2.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.